Lensar recently announced that it has received FDA 510(k) clearance for its laser system with Streamline IV for micro radial incisions.
The laser technology allows surgeons to treat corneal conditions after cataract surgery.
“This indication is the latest example of Lensar responding to the needs and feedback from our customers, those refractive cataract surgeons looking to deploy from a full arsenal of treatment options that support their pursuit of best possible outcomes for patients,” Nicholas Curtis, CEO of Lensar, said in a press release. “Our top priority is continuing to build upon our foundation of adoptive innovation with relevant purposeful and continuous upgrades.”
Micro radial incisions that are performed with the Lensar Laser System are done through a femtosecond laser with powerful imaging capabilities, according to the company. It is fully programmable for depth, length and position by the surgeon based on data from the patient.
“The addition of the micro incisional capability to the existing suite of enhancements for managing astigmatism, including arcuate incisions, increases the value of the Lensar Laser System in delivering on the expectations of the premium cataract procedure,” Dr. Beau Swann of Brazos Eye Surgery in Texas, said. “Particularly for those patients who are not candidates for a Lasik or Smile procedure, this latest Lensar innovation offers the surgeon an additional option to improve a patient’s result and, ultimately, level of satisfaction with their choice of a customized, advanced procedure.”
